Rethinking Heart Attacks: New Framework Targets Plaques Before Arteries Narrow

For more than half a century, the management of coronary artery disease has been organized around a single anatomical question: how severely is the vessel narrowed? Cardiologists measure stenosis, look for ischemia, and intervene when blood flow through a coronary artery becomes sufficiently restricted to cause chest pain or damage the heart muscle. A new commentary published in Cardiology Discovery argues that this long-standing, ischemia-centered model is fundamentally misaligned with the biology of the disease it aims to prevent. Drawing on the framework proposed by The Lancet Commission, the authors call for coronary artery disease to be redefined as atherosclerotic coronary artery disease, or ACAD, and for clinical attention to shift decisively toward the atherosclerotic plaque itself as the true driver of heart attacks. The reframing is not merely semantic. It carries profound implications for who gets screened, when treatment begins, and which interventions are prioritized across the global burden of cardiovascular disease.

The central problem with the stenosis-centered model is that it intervenes too late. By the time a coronary artery is narrowed enough to produce angina or measurable ischemia, the underlying atherosclerotic process has usually been advancing silently for decades. More troubling still, the model fails to capture how most heart attacks actually occur. Myocardial infarction frequently results from the rupture or erosion of a plaque that never caused severe narrowing in the first place. A vessel that looks only mildly diseased on an angiogram can harbor an unstable, lipid-rich, inflamed lesion with a thin fibrous cap, poised to rupture and trigger an occlusive thrombus. Because such non-obstructive plaques fall below the threshold that traditionally triggers aggressive intervention, millions of asymptomatic but high-risk individuals receive no targeted preventive care until the moment their artery closes. The commentary identifies this gap as one of the most consequential missed opportunities in modern cardiology.

To ground the proposed shift in real-world evidence, the authors draw on population-based epidemiologic data from China, one of the largest and most rapidly aging populations in the world. Community-based studies there reveal the sheer scale of subclinical atherosclerosis: among adults aged 50 to 75 years in local community cohorts, coronary plaque prevalence reaches 44.9 percent, meaning nearly half of middle-aged and older adults already carry atherosclerotic lesions in their coronary arteries. The burden extends beyond the heart as well. More than one-fifth of Chinese adults aged 20 and older have plaques detectable in the carotid arteries, a finding that underscores how early and how systemically atherosclerosis begins to accumulate. These figures transform subclinical plaque from a niche imaging curiosity into a population-level phenomenon that primary care systems must be equipped to detect and manage.

The practical centerpiece of the commentary is a stepwise, risk-stratified screening workflow designed specifically for primary-care and resource-conscious settings. Rather than recommending universal advanced imaging, the authors propose targeting adults aged 40 or older who carry at least one traditional cardiac risk factor, such as hypertension, diabetes, dyslipidemia, or current smoking. Initial evaluation relies on noninvasive, widely accessible tools, beginning with carotid ultrasound and coronary artery calcium scoring. Carotid ultrasound offers a window into the systemic atherosclerotic process at low cost and without radiation, while coronary artery calcium scoring quantifies the calcified plaque burden in the coronary arteries and has repeatedly demonstrated strong prognostic value for predicting future cardiac events. Only when these first-line tests reveal abnormalities does the pathway escalate toward more detailed assessment, avoiding the immediate deployment of costly intracoronary imaging techniques that cannot realistically be offered to entire at-risk populations.

Critically, the framework specifies what should happen once subclinical plaque is found. The presence of high-risk plaque features on imaging, or an elevated coronary artery calcium score, triggers intensified pharmacologic and lifestyle intervention rather than mechanical repair. Guideline-directed medical therapy, including aggressive lipid lowering, blood pressure control, antithrombotic strategies where indicated, smoking cessation, and dietary and physical activity modification, forms the therapeutic backbone. The authors are explicit on a point that challenges much routine practice: existing evidence does not support routine stenting of non-culprit vulnerable plaques. Stenting a lesion that has never caused symptoms or flow limitation exposes patients to procedural risk without a demonstrated reduction in future myocardial infarction, because the plaque that ultimately ruptures may be a different lesion entirely. Systemic medical therapy, by contrast, treats the whole coronary tree and the diffuse disease process that produced the vulnerable plaque in the first place.

One of the most forward-looking elements of the commentary is its insistence that plaque stability is governed by more than cholesterol. Lipid lowering remains foundational, and the demonstrated efficacy of statins and newer agents in reducing cardiovascular events justifies its central place. But the authors emphasize residual inflammatory risk as an independent and modifiable determinant of plaque vulnerability. Inflammation within the plaque microenvironment drives cap thinning, neovascularization, and propensity to rupture, and emerging anti-inflammatory approaches aim to address this axis directly. The commentary also widens the lens to environmental exposures, highlighting fine particulate air pollution and traffic noise as contributors to atherosclerotic progression and cardiovascular risk. Integrating inflammation control and environmental risk mitigation into plaque-centered care represents a genuinely systemic vision, one in which cardiology collaborates with public health, urban planning, and environmental policy rather than operating solely within the catheterization laboratory.

The authors are notably candid about the limitations of their proposal, a transparency that strengthens rather than weakens the argument. Advanced plaque imaging, including intracoronary optical coherence tomography and near-infrared spectroscopy, remains expensive and cannot be broadly deployed in resource-limited regions where much of the global cardiovascular burden resides. Standardization of image reading across centers is still incomplete, raising concerns about consistency in how high-risk plaque features are identified and acted upon. Most importantly, definitive long-term randomized controlled trial evidence demonstrating that plaque-targeted screening reduces hard clinical endpoints, such as myocardial infarction and cardiovascular mortality, has not yet been generated. Anti-inflammatory add-on therapies, while biologically compelling, require further real-world validation of their safety profiles and cost-effectiveness before they can be recommended at scale. The commentary therefore positions plaque-guided care as a promising, evidence-informed model awaiting confirmatory trials, not as a settled standard.

The implications for health systems, particularly those in low- and middle-income countries undergoing rapid epidemiologic transition, are substantial. Coronary artery disease remains the leading cause of death worldwide, and the demographic momentum of aging populations ensures that the number of individuals living with subclinical atherosclerosis will continue to grow. A screening strategy built on inexpensive carotid ultrasound and calcium scoring, coupled with intensified medical therapy for those who test positive, could in principle be implemented far more broadly than imaging-intensive or procedure-heavy alternatives. It also realigns incentives: instead of rewarding the treatment of late-stage obstruction, a plaque-centered system rewards the early identification and stabilization of disease, potentially preventing the acute events that generate the greatest costs and the greatest suffering. Whether health systems can reorganize financing, training, and referral pathways to support this shift remains an open and urgent question.

What emerges from the commentary is a coherent vision of cardiovascular medicine reoriented around disease biology rather than anatomical symptoms. The Lancet Commission’s redefinition of coronary disease as atherosclerotic coronary artery disease provides the conceptual foundation, and the Chinese population data provide a sobering measure of the task ahead: nearly half of adults in their fifties through mid-seventies already carry coronary plaques, most of them undetected and untreated. The path forward proposed by the authors is pragmatic, beginning in primary care with risk-stratified screening, escalating therapy according to plaque burden and vulnerability, reserving revascularization for lesions that genuinely warrant it, and addressing the inflammatory and environmental drivers of plaque instability alongside lipids. Large prospective outcome studies and cost-effectiveness analyses will determine how quickly and how widely this model can be validated and adopted. If those trials confirm the promise of plaque-guided prevention, the current paradigm of waiting for arteries to narrow before acting may come to be seen as one of cardiology’s most costly delays.

Subject of Research: Plaque-centered early intervention and risk-stratified screening for atherosclerotic coronary artery disease

Article Title: New clinical framework shifts coronary disease care away from vessel narrowing toward atherosclerotic plaque centered early intervention

Article References: New clinical framework shifts coronary disease care away from vessel narrowing toward atherosclerotic plaque centered early intervention. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: coronary artery disease, atherosclerotic plaque, ACAD, Lancet Commission, coronary artery calcium, carotid ultrasound, plaque rupture, inflammation, air pollution, primary care screening, medical therapy, cardiovascular prevention